Literature DB >> 15551208

Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells.

Ming Qiao1, Mundrigi Ashok, Kristen A Bernard, Gustavo Palacios, Z Hong Zhou, W Ian Lipkin, T Jake Liang.   

Abstract

No specific vaccine for West Nile virus (WNV) is currently available for human use. In the present study, we describe the generation of WNV-like particles (WNV-LPs) in insect cells by use of recombinant baculoviruses expressing the WNV structural proteins prME or CprME. BALB/c mice immunized with purified WNV-LPs developed WNV-specific antibodies that had potent neutralizing activities. Mice immunized with prME-like particles (prME-LPs) showed no morbidity or mortality after challenge with WNV. Immunization with prME-LPs can induce sterilizing immunity without producing any evidence of viremia or viral RNA in the spleen or brain. These results suggest that WNV-LPs hold promise as a vaccine candidate for WNV infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551208     DOI: 10.1086/425933

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults.

Authors:  Rex Biedenbender; Joan Bevilacqua; Anne M Gregg; Mike Watson; Gustavo Dayan
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

2.  Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis.

Authors:  Nicholas O Fischer; Ernesto Infante; Tomohiro Ishikawa; Craig D Blanchette; Nigel Bourne; Paul D Hoeprich; Peter W Mason
Journal:  Bioconjug Chem       Date:  2010-06-16       Impact factor: 4.774

Review 3.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

4.  The TLR3 signaling complex forms by cooperative receptor dimerization.

Authors:  Joshua N Leonard; Rodolfo Ghirlando; Janine Askins; Jessica K Bell; David H Margulies; David R Davies; David M Segal
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-02       Impact factor: 11.205

5.  Monoclonal antibody-based competitive enzyme-linked immunosorbent assay for detecting and quantifying West Nile virus-neutralizing antibodies in horse sera.

Authors:  Kang-Seuk Choi; Young-Joon Ko; Jin-Ju Nah; Yong-Joo Kim; Shien-Young Kang; Kyoung-Jin Yoon; Yi-Seok Joo
Journal:  Clin Vaccine Immunol       Date:  2006-11-29

6.  Production of pseudoinfectious yellow fever virus with a two-component genome.

Authors:  Alexandr V Shustov; Peter W Mason; Ilya Frolov
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

7.  A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells.

Authors:  Nathalie Bonafé; Joseph A Rininger; Richard G Chubet; Harald G Foellmer; Stacey Fader; John F Anderson; Sandra L Bushmich; Karen Anthony; Michel Ledizet; Erol Fikrig; Raymond A Koski; Paul Kaplan
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

8.  Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice.

Authors:  Matthew D Dunn; Shannan L Rossi; Donald M Carter; Matthew R Vogt; Erin Mehlhop; Michael S Diamond; Ted M Ross
Journal:  Virol J       Date:  2010-05-12       Impact factor: 4.099

Review 9.  Viral surveillance and discovery.

Authors:  Walter Ian Lipkin; Cadhla Firth
Journal:  Curr Opin Virol       Date:  2013-04-17       Impact factor: 7.090

10.  Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector.

Authors:  Travis J Taylor; Fernando Diaz; Robert C Colgrove; Kristen A Bernard; Neal A DeLuca; Sean P J Whelan; David M Knipe
Journal:  Virology       Date:  2016-06-20       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.